Remove Antibody Remove Gene Editing Remove Reagent Remove Scientist
article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies?   To what do you attribute your success?

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents.

article thumbnail

CRISPR breakthroughs: New solutions for common diseases

Drug Discovery World

Nucleic acid-based diagnostics, which typically require PCR reagents and laboratory equipment, are crucial for identifying, treating, and preventing common infectious diseases. While type II (Cas9) is mainly used for gene-editing applications, CRISPR detecting tools primarily rely on type V (Cas12) and type VI (Cas13) collateral activity.

DNA 98